A crucial factor in its development and treatment resistance is tumor hypoxia, which drives metabolic reprogramming (especially reconfiguration towards glycolysis), mediated to a great extent by hypoxia‐inducible factor‐“HIF‐1 alpha” (HIF‐1a). Here, HIF1A is linked to neoplasm.